Filing identity and reporting period
The supplied filing is Leap Therapeutics, Inc. (Nasdaq: LPTX), not Cypherpunk Technologies Inc. It is a Form 10-Q for the quarter ended September 30, 2023, filed November 13, 2023. Investors should confirm that this is the intended filing before relying on this summary.
Leap is a clinical-stage biopharmaceutical company developing antibody therapies for cancer. Its programs include DKN-01, FL-301, and preclinical FL-302 and FL-501. It has no approved products or product-sales revenue.
Financial results and position
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | No product revenue reported | No product revenue reported | No product revenue reported | No product revenue reported |
| Research and development expense | $11.5 million | $12.1 million | $61.5 million | $33.9 million |
| General and administrative expense | $3.3 million | $3.2 million | $10.7 million | $8.9 million |
| Net loss | $13.7 million | $15.1 million | $68.9 million | $42.5 million |
| Net loss per share, basic and diluted | $0.51 | $1.33 | $3.78 | $3.75 |
| Cash used in operating activities | Not presented quarterly | $33.4 million | $36.0 million |
At September 30, 2023, cash and cash equivalents were $80.7 million, versus $65.5 million at December 31, 2022. Current assets were $81.8 million and current liabilities $11.0 million. Total liabilities were $11.0 million, consisting principally of payables, accruals, and lease liabilities; the filing reports no borrowings. The company stated that cash should fund operating expenses for at least 12 months from issuance of the financial statements. It expects continued operating losses and may seek additional financing or collaboration funding.
Changes from comparable periods
- Q3 operating expenses declined $0.5 million and net loss narrowed $1.4 million year over year. R&D expense decreased $0.6 million, mainly due to lower manufacturing costs, partly offset by higher clinical-trial and payroll costs. Interest income rose to $1.1 million from $0.4 million.
- Nine-month operating expenses rose $29.4 million and net loss widened $26.5 million. R&D included a $29.6 million noncash charge for acquired in-process research and development from the Flame Biosciences transaction. Excluding the acquisition charge, reported R&D spending also reflected higher payroll and clinical-trial costs, partly offset by lower manufacturing expense.
- Operating cash use was $33.4 million, compared with $36.0 million a year earlier. Cash increased by $15.2 million over the nine months, substantially reflecting $50.4 million of cash acquired with Flame, net of acquisition-related costs; this increase was not generated by operations.
- Shares issued and outstanding rose from 9.9 million at December 31, 2022 to 25.6 million at September 30, 2023, largely reflecting consideration for Flame and conversion of Series X preferred stock. A one-for-ten reverse stock split took effect in June; share and per-share figures are retroactively adjusted in the filing.
Business developments, outlook, and risks
- Leap acquired Flame in January 2023, accounting for the transaction as an asset acquisition. It acquired cash and clinical- and preclinical-stage intellectual property. The company expensed $29.6 million of acquired IPR&D because it had no alternative future use. Certain additional merger consideration may be payable if specified Flame assets are sold, subject to the agreement’s terms.
- For DKN-01, the company expected to present updated long-term Part A DeFianCe colorectal-cancer data in early 2024. It reported that initial Part A results showed objective response above 20% and that the study had expanded into a 130-patient randomized Part B. Part C of the DisTinGuish gastric-cancer study was ongoing. Previously presented Part A data included 73% objective response in the modified intent-to-treat population, 85% in the PD-L1-low subgroup, median overall survival of 19.5 months, and median progression-free survival of 11.3 months.
- BeiGene declined in March 2023 to exercise its option for DKN-01 rights in specified Asia-Pacific territories; the parties’ agreement continues as a clinical collaboration.
- The company plans to increase R&D spending as development continues, subject to funding. Clinical development costs and timelines remain uncertain, including trial results, enrollment, regulatory requirements, and approvals. If funding or cost-sharing is unavailable, Leap may delay, reduce, or eliminate trials and research programs.
- Additional risks include dependence on unapproved investigational products, need for future financing, currency fluctuations, and potential clinical, regulatory, manufacturing, and supply-chain delays. DKN-01 and FL-301 have not been approved or submitted for FDA approval. The company reported no material legal proceedings and stated that disclosure controls were effective.
Most important facts to verify
- Confirm the filing issuer is Leap Therapeutics, Inc. and not Cypherpunk Technologies Inc.
- Review cash burn and runway assumptions against the stated 12-month funding horizon, including the timing and size of potential financing needs.
- Separate recurring operating costs from the $29.6 million Flame IPR&D charge and the $50.4 million of acquired cash when assessing trends and cash generation.
- Check subsequent clinical-trial updates and whether anticipated DKN-01 data presentations and study milestones occurred as expected.
- Assess dilution and potential equity overhang, including the increased share count, outstanding options and warrants, and the effect of the reverse split.